Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
- 1 May 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (13), 3125-3137
- https://doi.org/10.1200/jco.2005.00.224
Abstract
The best treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) is still debated. To guide clinical management of these patients and suggest the priorities for clinical research in this field, an International Expert Panel met in Naples, Italy, on April 19 to 20, 2004. Results and conclusions based on a review of evidence available in the literature to date are presented in this article. A comprehensive geriatric assessment is recommended to better define prognosis and to predict tolerance to treatment. In the first randomized study dedicated to elderly NSCLC patients, single-agent vinorelbine showed superiority over supportive care alone, both in terms of survival and quality of life. In a large randomized trial, gemcitabine plus vinorelbine failed to show any advantage over either agent alone. Subset analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with an acceptable increase in toxicity for elderly patients. These data should be interpreted cautiously because retrospective subgroup analyses are encumbered by selection bias; hence, randomized trials dedicated to platinum-based chemotherapy for nonselected elderly patients are warranted. Several promising biologic therapies are under investigation; however, with present data, target-based agents as first-line treatment for elderly NSCLC patients are not yet recommended. Clinical research, with trials specifically designed for elderly patients, is mandatory. With the current evidence, single-agent chemotherapy with a third-generation drug (vinorelbine, gemcitabine, a taxane) should be the recommended option for nonselected elderly patients with advanced NSCLC. Platinum-based chemotherapy is a viable option for fit patients with adequate organ function. Best supportive care remains important, in addition to chemotherapy or as the exclusive option for patients who are unsuitable for more aggressive treatment.Keywords
This publication has 92 references indexed in Scilit:
- Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialEuropean Journal Of Cancer, 2004
- Long-term trends in cancer mortality in the United States, 1930-1998Cancer, 2003
- Geriatric oncologyEuropean Journal Of Cancer, 2003
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Geriatric oncologyEuropean Journal Of Cancer, 2000
- Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinomaCancer, 2000
- Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatinCancer, 1999
- Lung cancer in the elderlyEuropean Journal Of Cancer, 1997
- Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II studyEuropean Journal Of Cancer, 1997
- Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patientsEuropean Journal Of Cancer, 1996